Matinas BioPharma Holdings, Inc. (NYSEMKT:MTNB)

CAPS Rating: 1 out of 5

MTNB News and Commentary

Caps

How do you think MTNB will perform against the market?

Add Stock to CAPS Watchlist

All Players

3 Outperform
14 Underperform
 

All-Star Players

1 Outperform
10 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top MTNB Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Top Bull Pitch

There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches below!

TSIF (99.97)
Submitted January 30, 2017

ACEOTC$118M Market cap which is 47X book (0.05)."a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. "14 Nov 2016 10-K"We are a clinical stage company… More

MTNB VS S&P 500 (SPY)

MTNB Summary

Fools bullish on MTNB are also bullish on:

Recent Community Commentary

Read the most recent pitches from players about MTNB.

Recs

0
Member Avatar RRobertsmith (61.69) Submitted: 6/27/2017 7:22:06 PM : Underperform Start Price: $1.79 MTNB Score: +24.11

"We will need to generate significant revenues to achieve profitability, and we may never do so. "

Recs

3
Member Avatar TSIF (99.97) Submitted: 1/30/2017 3:49:42 PM : Underperform Start Price: $2.15 MTNB Score: +43.35

ACE

OTC

$118M Market cap which is 47X book (0.05).
"a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. "

14 Nov 2016 10-K
"We are a clinical stage company and have generated $194,000 and $0 in contract research revenues during the nine months ended September 30, 2015 and September 30, 2016, respectively. These contract research revenues ended during 2015 and we do not anticipate any revenues during the remainder of 2016. We have incurred losses for each period from inception. Our net loss was approximately $5.7 million and $7.1 million for the nine months ended September 30, 2016 and 2015, respectively. Our net loss attributable to common shareholders was $11.8 million and $0 for the nine months ended September 30, 2016 and 2015, respectively. We expect to incur significant expenses and increasing operating losses for the foreseeable future. We expect our expenses to increase significantly in connection with our ongoing activities to develop, seek regulatory approval and commercialization of MAT2203 and MAT2501 and any other product candidates we choose to develop based upon our platform technology. Accordingly, we will need additional financing to support our continuing operations. We will seek to fund our operations through public or private equity or debt financings or other sources, which may include collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would impact our going concern and would have a negative impact on our financial condition and our ability to pursue our business strategy and continue as a going concern. We will need to generate significant revenues to achieve profitability, and we may never do so. "

Target 0.08

Recs

0
Member Avatar kdakota630 (30.32) Submitted: 1/27/2017 1:23:28 PM : Underperform Start Price: $2.04 MTNB Score: +39.13

Vague, generic, useless pitch. (Thanks to SmartAce for the find.)

Leaderboard

Find the members with the highest scoring picks in MTNB.

Score Leader

jon5555

jon5555 (96.92) Score: +78.16

The Score Leader is the player with the highest score across all their picks in MTNB.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
dedy2000 69.56 3/14/2017 Underperform 5Y $3.47 -60.81% +2.41% +63.22 0 Comment
tycoon24 98.01 2/8/2017 3/15/2017 Underperform 3M $2.67 -49.06% +6.04% +55.10 0 Comment
johnnyrocku 99.83 2/6/2017 Underperform 5Y $2.62 -48.07% +6.05% +54.12 0 Comment
tsperbeck 99.83 4/28/2017 Underperform 1Y $2.75 -50.55% +1.96% +52.50 0 Comment
cashole 99.86 1/31/2017 Underperform 3M $2.50 -45.60% +6.83% +52.43 0 Comment
RyanCoke 99.91 1/31/2017 Underperform NS $2.33 -41.63% +7.10% +48.73 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. TSIF 99.97 1/30/2017 Underperform 1Y $2.15 -36.74% +6.60% +43.35 1 Comment
JoeySolitro1 99.99 1/26/2017 Underperform 5Y $2.09 -34.93% +5.77% +40.70 0 Comment
ClientNein 99.98 1/26/2017 Underperform 5Y $2.07 -34.30% +5.83% +40.13 0 Comment
kdakota630 30.32 1/27/2017 Underperform 3M $2.04 -33.33% +5.79% +39.13 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for MTNB.

Featured Broker Partners